Understanding MYC: Why a Key Cancer Gene Is Hard to Stop

The MYC oncogene exerts widespread control over cell growth, metabolism and division, and its dysregulation is implicated in roughly 70% of human cancers, which helps explain why researchers consider it a central driver of tumor behavior. Because the MYC protein is intrinsically disordered, lacks a defined pocket for small molecules, and functions in the cell nucleus, it has long been labeled 'undruggable', so conventional drug discovery strategies have had limited success. Nevertheless, several laboratories have mapped regulatory DNA elements and epigenetic factors that sustain high MYC levels, revealing indirect vulnerabilities that could be exploited therapeutically.

For example, researchers studying pediatric medulloblastoma have identified an ecDNA-linked enhancer, called ecMYC E1, that drives high MYC expression in amplified tumors and can be disrupted to lower MYC levels, although cancer cells may adapt by increasing ecDNA copy number. Other teams have shown that chromatin-modifying enzymes—such as KDM4C and SETD2—act as gatekeepers for MYC amplification, suggesting that targeting these epigenetic regulators might prevent copy-number gains. These mechanistic insights have been reported in genomic and mouse studies and point to routes beyond direct MYC inhibition.

Drug platforms that degrade proteins (PROTACs), engineered peptides like Omomyc, and compounds that break oncogenic feedforward loops have produced promising preclinical activity against MYC-driven models. A biotech company has translated this progress into the clinic and recently treated the first patient in a Phase 2a trial of a MYC inhibitor, while other groups continue to refine enhancer- and epigenetic-targeting approaches. If these strategies can be shown to work safely in humans, they would mark a major shift in how the field confronts a gene long thought untouchable.